CN105832817A - Application of pyrroloquinoline quinine to treatment of burns, scalds and traumas - Google Patents
Application of pyrroloquinoline quinine to treatment of burns, scalds and traumas Download PDFInfo
- Publication number
- CN105832817A CN105832817A CN201610309901.8A CN201610309901A CN105832817A CN 105832817 A CN105832817 A CN 105832817A CN 201610309901 A CN201610309901 A CN 201610309901A CN 105832817 A CN105832817 A CN 105832817A
- Authority
- CN
- China
- Prior art keywords
- parts
- composition
- weight
- described compositions
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010053615 Thermal burn Diseases 0.000 title claims abstract description 23
- 208000014674 injury Diseases 0.000 title abstract description 11
- 230000008733 trauma Effects 0.000 title abstract description 6
- LOUPRKONTZGTKE-WZBLMQSHSA-N Quinine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-WZBLMQSHSA-N 0.000 title abstract 10
- ZIUYHTQZEPDUCZ-UHFFFAOYSA-N 7h-pyrrolo[2,3-h]quinoline Chemical compound C1=CN=C2C(C=CN3)=C3C=CC2=C1 ZIUYHTQZEPDUCZ-UHFFFAOYSA-N 0.000 title abstract 5
- 235000001258 Cinchona calisaya Nutrition 0.000 title abstract 5
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 title abstract 5
- 229960000948 quinine Drugs 0.000 title abstract 5
- 239000000203 mixture Substances 0.000 claims abstract description 104
- BLUAFEHZUWYNDE-NNWCWBAJSA-N artemisinin Chemical compound C([C@](OO1)(C)O2)C[C@H]3[C@H](C)CC[C@@H]4[C@@]31[C@@H]2OC(=O)[C@@H]4C BLUAFEHZUWYNDE-NNWCWBAJSA-N 0.000 claims abstract description 20
- 229960004191 artemisinin Drugs 0.000 claims abstract description 20
- MMXZSJMASHPLLR-UHFFFAOYSA-N pyrroloquinoline quinone Chemical compound C12=C(C(O)=O)C=C(C(O)=O)N=C2C(=O)C(=O)C2=C1NC(C(=O)O)=C2 MMXZSJMASHPLLR-UHFFFAOYSA-N 0.000 claims description 72
- 239000003814 drug Substances 0.000 claims description 24
- 229930191701 arteannuin Natural products 0.000 claims description 19
- 239000002674 ointment Substances 0.000 claims description 13
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 239000002552 dosage form Substances 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 3
- 239000000243 solution Substances 0.000 claims description 3
- 239000007921 spray Substances 0.000 claims description 3
- 208000027418 Wounds and injury Diseases 0.000 abstract description 34
- 206010052428 Wound Diseases 0.000 abstract description 30
- 238000000034 method Methods 0.000 abstract description 13
- 230000000694 effects Effects 0.000 abstract description 12
- 230000008569 process Effects 0.000 abstract description 11
- 230000029663 wound healing Effects 0.000 abstract description 6
- 231100000241 scar Toxicity 0.000 abstract description 5
- 230000035876 healing Effects 0.000 abstract description 4
- 230000008929 regeneration Effects 0.000 abstract description 4
- 238000011069 regeneration method Methods 0.000 abstract description 4
- 238000005469 granulation Methods 0.000 abstract description 3
- 230000003179 granulation Effects 0.000 abstract description 3
- 230000001338 necrotic effect Effects 0.000 abstract description 3
- 230000001737 promoting effect Effects 0.000 abstract description 3
- 206010040872 skin infection Diseases 0.000 abstract description 3
- 230000002087 whitening effect Effects 0.000 abstract description 3
- JDLKFOPOAOFWQN-VIFPVBQESA-N Allicin Natural products C=CCS[S@](=O)CC=C JDLKFOPOAOFWQN-VIFPVBQESA-N 0.000 abstract 1
- 241000894006 Bacteria Species 0.000 abstract 1
- 208000032544 Cicatrix Diseases 0.000 abstract 1
- 235000006679 Mentha X verticillata Nutrition 0.000 abstract 1
- 235000002899 Mentha suaveolens Nutrition 0.000 abstract 1
- 235000001636 Mentha x rotundifolia Nutrition 0.000 abstract 1
- JDLKFOPOAOFWQN-UHFFFAOYSA-N allicin Chemical compound C=CCSS(=O)CC=C JDLKFOPOAOFWQN-UHFFFAOYSA-N 0.000 abstract 1
- 235000010081 allicin Nutrition 0.000 abstract 1
- 229930101531 artemisinin Natural products 0.000 abstract 1
- 239000000463 material Substances 0.000 abstract 1
- 230000037387 scars Effects 0.000 abstract 1
- 230000008961 swelling Effects 0.000 abstract 1
- 231100000331 toxic Toxicity 0.000 abstract 1
- 230000002588 toxic effect Effects 0.000 abstract 1
- 239000007788 liquid Substances 0.000 description 41
- 239000002994 raw material Substances 0.000 description 20
- 210000003491 skin Anatomy 0.000 description 13
- 238000000703 high-speed centrifugation Methods 0.000 description 10
- 239000012535 impurity Substances 0.000 description 10
- 238000002791 soaking Methods 0.000 description 10
- 230000001954 sterilising effect Effects 0.000 description 10
- 238000011084 recovery Methods 0.000 description 9
- 230000006378 damage Effects 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- 210000000589 cicatrix Anatomy 0.000 description 7
- 230000006872 improvement Effects 0.000 description 6
- 208000025865 Ulcer Diseases 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 4
- 231100000397 ulcer Toxicity 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 210000002615 epidermis Anatomy 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000003440 toxic substance Substances 0.000 description 2
- 208000012260 Accidental injury Diseases 0.000 description 1
- 235000008733 Citrus aurantifolia Nutrition 0.000 description 1
- 206010011469 Crying Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 239000004100 Oxytetracycline Substances 0.000 description 1
- 206010039740 Screaming Diseases 0.000 description 1
- 206010040943 Skin Ulcer Diseases 0.000 description 1
- 208000028990 Skin injury Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 235000011941 Tilia x europaea Nutrition 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 229940097572 chloromycetin Drugs 0.000 description 1
- 229960003405 ciprofloxacin Drugs 0.000 description 1
- 238000010411 cooking Methods 0.000 description 1
- 238000001804 debridement Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000005187 foaming Methods 0.000 description 1
- 239000003721 gunpowder Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 235000000396 iron Nutrition 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 239000009416 jing wan hong Substances 0.000 description 1
- 210000002414 leg Anatomy 0.000 description 1
- 239000004571 lime Substances 0.000 description 1
- 210000001699 lower leg Anatomy 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 229960001180 norfloxacin Drugs 0.000 description 1
- OGJPXUAPXNRGGI-UHFFFAOYSA-N norfloxacin Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNCC1 OGJPXUAPXNRGGI-UHFFFAOYSA-N 0.000 description 1
- 229960000625 oxytetracycline Drugs 0.000 description 1
- IWVCMVBTMGNXQD-PXOLEDIWSA-N oxytetracycline Chemical compound C1=CC=C2[C@](O)(C)[C@H]3[C@H](O)[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-PXOLEDIWSA-N 0.000 description 1
- 235000019366 oxytetracycline Nutrition 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- APTZNLHMIGJTEW-UHFFFAOYSA-N pyraflufen-ethyl Chemical compound C1=C(Cl)C(OCC(=O)OCC)=CC(C=2C(=C(OC(F)F)N(C)N=2)Cl)=C1F APTZNLHMIGJTEW-UHFFFAOYSA-N 0.000 description 1
- 231100000075 skin burn Toxicity 0.000 description 1
- 231100000019 skin ulcer Toxicity 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- IWVCMVBTMGNXQD-UHFFFAOYSA-N terramycin dehydrate Natural products C1=CC=C2C(O)(C)C3C(O)C4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-UHFFFAOYSA-N 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/534—Mentha (mint)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Emergency Medicine (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention provides application of pyrroloquinoline quinine to treatment of burns, scalds and traumas. Pyrroloquinoline quinine is applied in the form of a composition. The composition is prepared from, by weight, 1-8 parts of pyrroloquinoline quinine, 2-9 parts of artemisinin, 2-8 parts of mint and 1-9 parts of allicin. Pyrroloquinoline quinine is applied in the form of the composition, in the process of treating the scalds, the burns and the traumas, regeneration and healing of trauma parts are promoted, the effects of stopping pain and subsiding swelling, removing necrotic tissue and promoting granulation, clearing away heat and toxic materials, achieving astriction and resisting bacteria are achieved, a good treatment effect is achieved for various trauma skin infections or deep skin tissue anabrosis which is not cured for a long time, face scars are removed, and the advantages that the pain of patients is small, wound healing is rapid, the wound surface restoration effect is good, the treatment time is short, the restoration effect is good, no scar is left, and face whitening and ultraviolet resisting are achieved.
Description
Technical field
The present invention relates to burn, scald and wound aspect medicine technology field, especially relate to pyrroloquinoline quinone application in terms for the treatment of burn, scald and wound.
Background technology
Along with the high speed development of urban industry, traffic, building industry etc., and the generation of natural disaster and thunder bolt, the probability that people's health comes to harm is increasing, and the burn, scald and the wound that cause also become increasingly complex.Scalding the accidental injury formula symptom referring to that human body exocuticle skin tissue is destroyed by high-temp liquid contact injury, burn refers to that human body exocuticle skin tissue is contacted by naked light or the most vehement roasting and damage formula symptom destroyed of coming to harm.Scald and burn is all that the attack of human skin tissue is destroyed by high temperature, cause the death of skin tissue cell, make skin histology can not exercise its normal physiological function again, thus threaten further and affect the tissue of skin bottom.This destructiveness can not only be expressed with destruction, but expresses with removing and disappearing, and makes the skin bottom tissue of people come out, and without the regeneration basis of skin, and skin around also will not be to side hypertrophy.
People treat scald and burn at present, typically just tackle infection with antibiotic or some antibacterial medicines and fester, and have smears Chinese medicine carelessly at wound area position blindly, and the injury effect played is more than therapeutical effect.The medicine of existing treatment skin burn also has multiple, and including Chinese medicine and Western medicine, such as conventional traditional Chinese herb medicine has JINGWANHONG RUANGAO, ointment for treating burn and scald, moist expose burn ointment etc.；Western medicine ointment has tetracycline ointment, oxytetracycline ointment, chloromycetin ointment, erythromycin ointment, ciprofloxacin ointment, norfloxacin ointment etc..According to Clinical practice for many years it has been observed that moist expose burn ointment curative effect is the best, but some patient occurs that allergic phenomena, therapeutic domain have certain limitation after using.Western medicine burn and scald, skin injury have certain therapeutic effect, but fall within selectivity application, it can therefore be appreciated that the therapeutic effect that existing medicine is in terms of burn, scald and wound is not fine, wound healing is slow, can also leave cicatrix.
Summary of the invention
In order to overcome the problems referred to above, the present invention provides pyrroloquinoline quinone at treatment burn to society, scalds and application in terms of wound, patient ache after a procedure bitter little, wound healing fast, wound surface recovery effects is good, treatment time is short, recovery effects is good and preventing from scar.
The technical scheme is that the application providing pyrroloquinoline quinone in terms for the treatment of burn, scald and wound, wherein, described pyrroloquinoline quinone is applied in the form of compositions, and described compositions is made up of the medicine of following composition by weight: pyrroloquinoline quinone 1-8 part, arteannuin 2-9 part, Herba Menthae 2-8 part, garlicin 1-9 part.
As improvement of the present invention, described compositions is made up of the medicine of following composition by weight: pyrroloquinoline quinone 2-7 part, arteannuin 3-8 part, Herba Menthae 3-7 part, garlicin 2-8 part.
As improvement of the present invention, described compositions is made up of the medicine of following composition by weight: pyrroloquinoline quinone 3-6 part, arteannuin 4-7 part, Herba Menthae 4-6 part, garlicin 3-7 part.
As improvement of the present invention, described compositions is made up of the medicine of following composition by weight: pyrroloquinoline quinone 5 parts, arteannuin 6 parts, Herba Menthae 5 parts, garlicin 5 parts.
As improvement of the present invention, the dosage form of described compositions includes: powder agent, solution, spray or ointment.
As improvement of the present invention, described pyrroloquinoline quinone is made by pure natural.
Present invention employs and state pyrroloquinoline quinone and apply in the form of compositions, scald in treatment, burn and during wound, promote regeneration and the healing of wound site, there is alleviating pain and detumescence, removing the necrotic tissue and promoting granulation, heat-clearing and toxic substances removing, restrain antibacterial effect, and also to various wound skin infections, or long-term deep skin histology ulcer the most etc. equal preferably imitate treatment, dispel face's cicatrix, there is patient and ache the advantages such as bitter little, wound healing fast, wound surface recovery effects is good, treatment time is short, recovery effects is good, preventing from scar, face's whitening and uvioresistant.
Detailed description of the invention
One, based on years of researches, research worker finds that pyrroloquinoline quinone has good using value in terms for the treatment of burn, scald and wound; therefore the present invention needs to be protected is pyrroloquinoline quinone application in terms for the treatment of burn, scald and wound; wherein; described pyrroloquinoline quinone is applied in the form of compositions, and described compositions is made up of the medicine of following composition by weight: pyrroloquinoline quinone 1-8 part, arteannuin 2-9 part, Herba Menthae 2-8 part, garlicin 1-9 part.
In the present invention, the dosage form of described compositions includes: powder agent, solution, spray or ointment, and described pyrroloquinoline quinone is made by pure natural.
In the present invention, the preparation method of described compositions, comprise the steps:
(100) Herba Menthae of 2-8 part (composition by weight), is taken:
(200), Herba Menthae is soaked the scheduled time, then the Herba Menthae after soaking is decocted, after decocting certain time, obtain raw material medicinal liquid；
(300), raw material medicinal liquid is carried out high speed centrifugation process, go the removal of impurity, obtain medicinal liquid；
(400), pyrroloquinoline quinone 1-8 part (composition by weight), arteannuin 2-9 part (composition by weight) and garlicin 1-9 part (composition by weight) are joined medicinal liquid obtains be mixed to get described compositions；
(500), described compositions carried out sterilizing and filter.
In the present invention, also including below embodiment, following example are used for illustrating the present invention, but are not limited to the scope of the present invention.
Embodiment 1
First, the Herba Menthae of 2 parts (composition by weight) is taken:
Secondly, Herba Menthae is soaked the scheduled time, then the Herba Menthae after soaking is decocted, after decocting certain time, obtain raw material medicinal liquid；Raw material medicinal liquid is carried out high speed centrifugation process, goes the removal of impurity, obtain medicinal liquid；Then pyrroloquinoline quinone 1 part (composition by weight), arteannuin 2 parts (composition by weight) and garlicin 1 part (composition by weight) are joined and obtain in medicinal liquid being mixed to get described compositions；Finally described compositions carried out sterilizing and filter.
Embodiment 2
First, the Herba Menthae of 3 parts (composition by weight) is taken:
Secondly, Herba Menthae is soaked the scheduled time, then the Herba Menthae after soaking is decocted, after decocting certain time, obtain raw material medicinal liquid；Raw material medicinal liquid is carried out high speed centrifugation process, goes the removal of impurity, obtain medicinal liquid；Then pyrroloquinoline quinone 2 parts (composition by weight), arteannuin 3 parts (composition by weight) and garlicin 2 parts (composition by weight) are joined and obtain in medicinal liquid being mixed to get described compositions；Finally described compositions carried out sterilizing and filter.
Embodiment 3
First, the Herba Menthae of 4 parts (composition by weight) is taken:
Secondly, Herba Menthae is soaked the scheduled time, then the Herba Menthae after soaking is decocted, after decocting certain time, obtain raw material medicinal liquid；Raw material medicinal liquid is carried out high speed centrifugation process, goes the removal of impurity, obtain medicinal liquid；Then pyrroloquinoline quinone 3 parts (composition by weight), arteannuin 4 parts (composition by weight) and garlicin 3 parts (composition by weight) are joined and obtain in medicinal liquid being mixed to get described compositions；Finally described compositions carried out sterilizing and filter.
Embodiment 4
First, the Herba Menthae of 4.7 parts (composition by weight) is taken:
Secondly, Herba Menthae is soaked the scheduled time, then the Herba Menthae after soaking is decocted, after decocting certain time, obtain raw material medicinal liquid；Raw material medicinal liquid is carried out high speed centrifugation process, goes the removal of impurity, obtain medicinal liquid；Then pyrroloquinoline quinone 3.4 parts (composition by weight), arteannuin 4.5 parts (composition by weight) and garlicin 3.5 parts (composition by weight) are joined and obtain in medicinal liquid being mixed to get described compositions；Finally described compositions carried out sterilizing and filter.
Embodiment 5
First, the Herba Menthae of 5 parts (composition by weight) is taken:
Secondly, Herba Menthae is soaked the scheduled time, then the Herba Menthae after soaking is decocted, after decocting certain time, obtain raw material medicinal liquid；Raw material medicinal liquid is carried out high speed centrifugation process, goes the removal of impurity, obtain medicinal liquid；Then pyrroloquinoline quinone 5 parts (composition by weight), arteannuin 6 parts (composition by weight) and garlicin 5 parts (composition by weight) are joined and obtain in medicinal liquid being mixed to get described compositions；Finally described compositions carried out sterilizing and filter.
Embodiment 6
First, the Herba Menthae of 6 parts (composition by weight) is taken:
Secondly, Herba Menthae is soaked the scheduled time, then the Herba Menthae after soaking is decocted, after decocting certain time, obtain raw material medicinal liquid；Raw material medicinal liquid is carried out high speed centrifugation process, goes the removal of impurity, obtain medicinal liquid；Then pyrroloquinoline quinone 6 parts (composition by weight), arteannuin 7 parts (composition by weight) and garlicin 7 parts (composition by weight) are joined and obtain in medicinal liquid being mixed to get described compositions；Finally described compositions carried out sterilizing and filter.
Embodiment 7
First, the Herba Menthae of 6.5 parts (composition by weight) is taken:
Secondly, Herba Menthae is soaked the scheduled time, then the Herba Menthae after soaking is decocted, after decocting certain time, obtain raw material medicinal liquid；Raw material medicinal liquid is carried out high speed centrifugation process, goes the removal of impurity, obtain medicinal liquid；Then pyrroloquinoline quinone 6.4 parts (composition by weight), arteannuin 7.6 parts (composition by weight) and garlicin 7.3 parts (composition by weight) are joined and obtain in medicinal liquid being mixed to get described compositions；Finally described compositions carried out sterilizing and filter.
Embodiment 8
First, the Herba Menthae of 7 parts (composition by weight) is taken:
Secondly, Herba Menthae is soaked the scheduled time, then the Herba Menthae after soaking is decocted, after decocting certain time, obtain raw material medicinal liquid；Raw material medicinal liquid is carried out high speed centrifugation process, goes the removal of impurity, obtain medicinal liquid；Then pyrroloquinoline quinone 7 parts (composition by weight), arteannuin 8 parts (composition by weight) and garlicin 8 parts (composition by weight) are joined and obtain in medicinal liquid being mixed to get described compositions；Finally described compositions carried out sterilizing and filter.
Embodiment 9
First, the Herba Menthae of 8 parts (composition by weight) is taken:
Secondly, Herba Menthae is soaked the scheduled time, then the Herba Menthae after soaking is decocted, after decocting certain time, obtain raw material medicinal liquid；Raw material medicinal liquid is carried out high speed centrifugation process, goes the removal of impurity, obtain medicinal liquid；Then pyrroloquinoline quinone 8 parts (composition by weight), arteannuin 9 parts (composition by weight) and garlicin 9 parts (composition by weight) are joined and obtain in medicinal liquid being mixed to get described compositions；Finally described compositions carried out sterilizing and filter.
Two, below by clinical data, pyrroloquinoline quinone application in terms for the treatment of burn, scald and wound being described, wherein, described pyrroloquinoline quinone is applied with the form of described compositions:
1, clinical observation: the described compositions in the present invention is since 2006 to 2015 years hospitals throughout the country carry out Clinical practice, receive altogether and cure burn, scald, scratch, knife injury, hard defects and patient 1000 example of other wound, wherein fire victim 300 example, scald patient 400 example, scratch patient 100 example, knife injury patient 80 example, hard defects patient 70 example and other trauma patient 50 example.
2, instructions of taking:
Cleaning with normal saline, distilled water, cold water or mineral water and pollute wound surface, person cuts off part bubble skin blister, blots wound surface cleanout fluid.Described compositions is directly coated on wound surface by large area, deep burn patient, again coats once every 3 hours later, it is not necessary to wrapping.Described compositions is directly coated on wound surface by the burned patient for small areas, again coats once every 5 hours later, it is not necessary to wrapping.Use other medicines to use described compositions instead, the left drug of wound surface must have been cleaned up, after blotting cleanout fluid, coat described compositions.Before medication next day, using described compositions again after cleaning wound surface with above-mentioned same method, administration time is identical.During wound surface incrustation, it is sure not to think stripping crust so that it is naturally come off, after crust completely falls off, continuation medication 3-5 days, every day 2 times.
3, dietetic contraindication: simultaneously should not take with other Chinese medicine when taking, gives up alcohol, maror.
4, efficacy result:
The healing ultrahigh in efficiency of the present invention as can be seen from the table, reaches 97.5%, evident in efficacy.
5, some cases data:
Case 1: Liu so-and-so, female, 25 years old, Foshan people from city, boiled water irons the back of the hand, serious local foaming scaling, utilize heretofore described compositions smear only once week basic rehabilitation, epidermis does not stays cicatrix.
Case 2: Zhang, man, 10 years old, people from Changsha, imprudence is fallen in the lime pile in building site, left foot and the swollen bubble of leg burn, the heretofore described compositions of external, three times a day, and recovery from illness in 15 days, do not stay cicatrix.
Case 3: Hu, man, 55 years old, people from Jingmen, Hubei, burnt red iron plate and burnt, epidermis is the most downright bad, subcutaneous outward appearance pale muddiness or pale brown, the heretofore described compositions of external, and within 20 days, symptom substantially alleviates, and gradually takes a turn for the better, and neoplastic skin starts to generate.
Case 4: king so-and-so, female, 19 years old, people from Shaoyang, Hunan, during cooking, scalded arm by boiled oil, utilize the present invention to smear treatment, fully recover after 15 days, without cicatrix.
Case 5: Zheng, man, 33 years old, liuyang hunan people, during firecrackers processed, gunpowder is ignited, the right hand of burning, utilize the present invention to smear treatment, first deposited with changing wiping after soak into, fully recover after 14 days, do not stay cicatrix.
Case 6: Wu so-and-so, female, 2 years old, people from Chengdu, Sichuan, accidentally by the most boiled scald right hand, there is redness in local, and a large amount of blister part ulcerations are peeled, debridement immediately after being admitted to hospital, hindering the topcoating present invention, stopping of crying and screaming after 30 minutes, the heretofore described compositions of external, recovery from illness in 8 days is left hospital.
Case 7: leaf so-and-so, man, 40 years old, Chongqing people from Dazhou City, accidentally ride motor overturning wound, once treating 15 days at certain hospital, doctor advised is selected a time dermatoplastic treatment, it is considered to financial expenditure is big, financial insolvency is left hospital automatically, the heretofore described compositions of external later, within 25 days, wound healing is left hospital, and follows up a case by regular visits to have no recurrence after half a year.
Case 8: what so-and-so, female, 45 years old, people from Hanzhong, to suppurate without bright reason right crus of diaphragm skin ulcer, local hospital wrapping is changed dressings infusion treatment one month, and ulcer has no improvement, the heretofore described compositions of external later, follows up a case by regular visits to ulcer and heal after 15 days.
Case 9: congratulate so-and-so, man, 55 years old, people from Xi'an, Shaanxi, family catches fire, by back large-area burns, the heretofore described compositions of external later, recovery from illness in 30 days is left hospital.
State pyrroloquinoline quinone described in present invention employs to apply in the form of compositions, scald in treatment, burn and during wound, promote regeneration and the healing of wound site, there is alleviating pain and detumescence, removing the necrotic tissue and promoting granulation, heat-clearing and toxic substances removing, restrain antibacterial effect, and also to various wound skin infections, or long-term deep skin histology ulcer the most etc. equal preferably imitate treatment, dispel face's cicatrix, there is patient and ache the advantages such as bitter little, wound healing fast, wound surface recovery effects is good, treatment time is short, recovery effects is good, preventing from scar, face's whitening and uvioresistant.
Claims (6)
1. pyrroloquinoline quinone application in terms for the treatment of burn, scald and wound, wherein, described pyrroloquinoline quinone is applied in the form of compositions, and described compositions is made up of the medicine of following composition by weight: pyrroloquinoline quinone 1-8 part, arteannuin 2-9 part, Herba Menthae 2-8 part, garlicin 1-9 part.
Application the most according to claim 1, it is characterised in that: described compositions is made up of the medicine of following composition by weight: pyrroloquinoline quinone 2-7 part, arteannuin 3-8 part, Herba Menthae 3-7 part, garlicin 2-8 part.
Application the most according to claim 1, it is characterised in that: described compositions is made up of the medicine of following composition by weight: pyrroloquinoline quinone 3-6 part, arteannuin 4-7 part, Herba Menthae 4-6 part, garlicin 3-7 part.
Application the most according to claim 1, it is characterised in that: described compositions is made up of the medicine of following composition by weight: pyrroloquinoline quinone 5 parts, arteannuin 6 parts, Herba Menthae 5 parts, garlicin 5 parts.
5. according to the application described in any one claim in claim 1-4, it is characterised in that: the dosage form of described compositions includes: powder agent, solution, spray or ointment.
6. according to the application described in any one claim in claim 1-4, it is characterised in that: described pyrroloquinoline quinone is made by pure natural.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610309901.8A CN105832817B (en) | 2016-05-11 | 2016-05-11 | Application of pyrroloquinoline quinine to pharmaceutical compositions for treatment of burns, scalds and traumas |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610309901.8A CN105832817B (en) | 2016-05-11 | 2016-05-11 | Application of pyrroloquinoline quinine to pharmaceutical compositions for treatment of burns, scalds and traumas |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN105832817A true CN105832817A (en) | 2016-08-10 |
| CN105832817B CN105832817B (en) | 2017-02-22 |
Family
ID=56591787
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610309901.8A Active CN105832817B (en) | 2016-05-11 | 2016-05-11 | Application of pyrroloquinoline quinine to pharmaceutical compositions for treatment of burns, scalds and traumas |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105832817B (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110478349A (en) * | 2019-09-23 | 2019-11-22 | 黑龙江中医药大学 | A kind of wound care dressing and preparation method thereof |
| CN116850085A (en) * | 2023-08-18 | 2023-10-10 | 水羊化妆品制造有限公司 | Application of pyrroloquinoline quinone disodium salt in repairing skin barrier |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105147881A (en) * | 2015-10-28 | 2015-12-16 | 李琳 | Compound menthol balm for treating burns |
-
2016
- 2016-05-11 CN CN201610309901.8A patent/CN105832817B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105147881A (en) * | 2015-10-28 | 2015-12-16 | 李琳 | Compound menthol balm for treating burns |
Non-Patent Citations (2)
| Title |
|---|
| 孙静娴等: "吡咯喹啉醌生理医学功效研究进展", 《生物学杂志》 * |
| 李皓桓等: "吡咯喹啉醌对放创性皮肤损伤促愈合研究", 《中华放射医学与防护杂志》 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110478349A (en) * | 2019-09-23 | 2019-11-22 | 黑龙江中医药大学 | A kind of wound care dressing and preparation method thereof |
| CN110478349B (en) * | 2019-09-23 | 2022-11-15 | 黑龙江中医药大学 | Dressing for wound care and preparation method thereof |
| CN116850085A (en) * | 2023-08-18 | 2023-10-10 | 水羊化妆品制造有限公司 | Application of pyrroloquinoline quinone disodium salt in repairing skin barrier |
Also Published As
| Publication number | Publication date |
|---|---|
| CN105832817B (en) | 2017-02-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101310748A (en) | Ointment for treating empyrosis | |
| CN102512542A (en) | A pharmaceutical composition for treating skin wounds and its preparation method | |
| CN102357203B (en) | Cortex ulmis burn ointment for curing burns | |
| CN103055052A (en) | Cream for treating burn and scald and preparation method of cream | |
| CN101455748B (en) | Inflammation-diminishing tissue-regeneration medicine and preparation method thereof | |
| CN107913338A (en) | A kind of medicine for treating burn and scald ulcer and preparation method thereof | |
| CN1052881C (en) | Burn and scald ointment | |
| CN105832817B (en) | Application of pyrroloquinoline quinine to pharmaceutical compositions for treatment of burns, scalds and traumas | |
| CN104815172A (en) | Scald ointment as well as preparation method and application method of scald ointment | |
| CN103054959A (en) | Specific burn treatment liquid | |
| KR101374537B1 (en) | Pharmaceutical Composition for Burn Treatment Using Gombo-Baechu | |
| CN102293783B (en) | Traditional Chinese medicinal composition for treating bedsore | |
| CN101297866B (en) | Chinese medicament oil solution for treating burn and preparation thereof | |
| CN109045204A (en) | A kind of herb liquid and preparation method thereof for treating burn and scald | |
| CN101108238A (en) | Burned muscle reproducing oil and method of preparing the same | |
| CN102688368B (en) | Traditional Chinese medicine for treating trauma hemostasis or telephium | |
| CN102198212B (en) | Chinese medicinal liquid for treating burns and scalds and preparation method thereof | |
| CN101690753B (en) | Chinese medicament preparation for treating burn injuries and preparation method thereof | |
| CN111991471A (en) | A topical Chinese medicinal preparation for treating knife wound, burn and scald, and its preparation method | |
| CN113197973A (en) | Pharmaceutical composition and preparation method thereof | |
| CN106728069B (en) | Slough-removing and tissue regeneration-promoting paste for treating scalds and burns | |
| CN1304028C (en) | Medicinal powder for treating burn and scald | |
| CN102166283B (en) | Externally-applied treatment fluid for treating burns and scalds and preparation method thereof | |
| CN102813828B (en) | Stropanthus divericatus for treating external wounds | |
| CN103127483B (en) | External-application medicine used for treating vasculitis, and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |